IDEXX Laboratories, Inc. (IDXX)
Nasdaq · Westbrook, Maine, USA · Founded 1983 · CEO Jonathan Mazelsky
Valuation summary
$268.00 fair value versus $689.65 in the market, a difference of -61.1%. Rated Sell.
| Fair value per share | $268.00 |
| Current share price | $689.65 |
| Upside / downside | -61.1% |
| Bear case | $172.64 |
| Bull case | $405.00 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.80% |
| Market capitalisation | $54B |
| EV / Sales | 12.0x |
About IDEXX Laboratories, Inc.
Founded in 1983. IDEXX makes veterinary diagnostic equipment and the test consumables that run on it, plus practice management software for animal clinics. The model mirrors razor-and-blades: place an analyser in a veterinary practice, then sell the proprietary test slides it consumes for years afterwards. It holds a dominant position in companion animal diagnostics.
Investment case
- Installed analysers lock in years of high-margin consumable revenue.
- Pet healthcare spending has proved resilient through economic cycles.
- Diagnostic testing rates per veterinary visit continue to rise.
Key risks
- Veterinary clinic visit volumes have softened as pandemic-era pet adoption normalises.
- Persistently expensive relative to almost any comparable business.
- Veterinary staffing shortages constrain how many appointments clinics can run.
Recent developments
- 2026-10-01 · IDEXX will report third-quarter 2026 results before the market opens on 2 November 2026. source
- 2026-09-16 · IDEXX acquired CoVetAI, a veterinary workflow software company; terms not disclosed in the headline. source
- 2026-08-11 · IDEXX added a dual-species point-of-care NT-proBNP cardiac test to its Catalyst analyser platform. source
- 2026-08-04 · Q2 2026 revenue $1.217bn, up 10% (9% organic), EPS $4.27, up 18%; 2026 EPS outlook raised to $14.69-14.94. source
Revenue by segment
| Companion Animal Diagnostics | 87% |
| Water Testing | 7% |
| Livestock & Other | 6% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $5.2B | $1.0B |
| Year 2 | $5.8B | $1.1B |
| Year 3 | $6.4B | $1.2B |
| Year 4 | $7.0B | $1.3B |
| Year 5 | $7.7B | $1.4B |
What the street says
Regarded as an exceptional business model. The entire discussion is valuation and clinic visit trends. Second-quarter 2026 results, with 9% organic revenue growth and a full-year EPS outlook raised to $14.69–$14.94, kept the operating record intact.
Comparable companies: A · EW · RMD · ABT · SNY · DXCM · MDT · SYK
Open the interactive model, price chart and sensitivity grid →